The Japan Agency for Medical Research and Development (AMED) — a national funding agency created to support medical R&D in the Asian nation — has awarded up to $32 million to Epifrontier Therapeutics to advance the clinical development of EPF-001, its investigational therapy for sickle cell disease (SCD)…